Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?
Health Econ
.
1992 Jul;1(2):85-92.
doi: 10.1002/hec.4730010202.
Author
M Drummond
PMID:
1341931
DOI:
10.1002/hec.4730010202
No abstract available
Publication types
Editorial
MeSH terms
Australia
Cost-Benefit Analysis
Drug Costs
Drug Evaluation / methods*
Guidelines as Topic
Insurance, Pharmaceutical Services / standards*
Ontario
Reimbursement Mechanisms